Aura Biosciences has completed $30 million in Series C financing, according to a company press release.
Lundbeckfonden Ventures and Arix Bioscience led the funding, with the company’s current investors also participating, the release said.
The funding is expected to be used to advance clinical development of AU-011, a light-activated, targeted therapy for the treatment of ocular melanoma.
“This year has been one of incredible momentum for Aura, with interim positive data reported from our phase 1b/2 study of AU-011 and enthusiasm from key opinion leaders in ocular oncology across the
Uncategorized